Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

assistive technology

  • Home
  •  
  • assistive technology



  • Most Read
  • Latest Comments
  • Control Bionics to grow accessibility tech for the disabled with $15m IPO
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Control Bionics to grow accessibility tech for the disabled with $15m IPO
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Control Bionics to grow accessibility tech for the disabled with $15m IPO
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Control Bionics to grow accessibility tech for the disabled with $15m IPO
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Control Bionics to grow accessibility tech for the disabled with $15m IPO
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • PainChek locks in performance data for FDA submission, aiming to be  first pain assessment app approved in US
    PainChek locks in performance data for FDA submission, aiming to be first pain assessment app approved in US
    • News

  • HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    HeraMED eyes TGA reclassification to restore HeraBEAT device for at-home use
    • News

  • Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    Strategic win for Control Bionics as new HCPCS gets approved for NeuroNode
    • News

  • Nido Education flags profit downgrade amid delays in new childcare centre openings
    Nido Education flags profit downgrade amid delays in new childcare centre openings
    • News

  • dorsaVi secures $110k in contracts across mining, healthcare, and shipping sectors
    dorsaVi secures $110k in contracts across mining, healthcare, and shipping sectors
    • News

  • Control Bionics to grow accessibility tech for the disabled with $15m IPO
    • News

    Control Bionics to grow accessibility tech for the disabled with $15m IPO

    Technology company, Control Bionics Limited (Proposed ASX: CBL) are one of the latest medtech companies looking to list on the exchange next month. The company is looking to raise $15m by November 25 at an offer price of $0.60 per share, giving the company an indicative market capitalization at the offer price of $50m.  The

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.